Ushering in a new era of anti-cancer, the world's first multimodal tumor treatment system, "Jiaofu" cooperation, "cold and hot" dual attack mode | tumor | treatment
How to ablate cancer cells? Let them freeze and heat up? That's right, a combination of cold and hot, multiple modalities, and finding new ways to treat tumors. On the 15th, a team of professors from Shanghai Jiao Tong University collaborated with clinical experts from Fudan University to conduct research and independent innovation. The world's first multimodal tumor treatment system was launched in Shanghai, using precise thermal dose control technology and organic fusion of tissue freezing and radiofrequency heating technology, ushering in a new era of human anti-cancer.
The incidence rate of cancer is rising day by day, while cutting-edge science and technology are making continuous progress. It is inevitable that cross-border cooperation will break through the limitations of single tumor diagnosis and treatment technology. The proposal of the concept of combination of medicine and equipment, the integration of multiple modal energy therapy technologies, breakthroughs in basic research of thermophysical immunology technology, and the support of artificial intelligence and big data technology have brought infinite possibilities for curing tumors.
As a result, the world's first multimodal tumor treatment system has been officially released and entered the clinical application stage. This achievement was created by the innovative team of Professor Xu Xuemin, Vice President of Shanghai Jiao Tong University, and clinical experts represented by Fudan University Affiliated Cancer Hospital, after years of interdisciplinary collaboration and cross disciplinary integration of medical and engineering. This original system was transformed by Shanghai Meijie Medical Technology Co., Ltd. and passed the special review procedure for national innovative medical devices. It just obtained the listing permit from the Drug Administration on June 9th this year.
Jiefang Daily's Shangguan News reporter learned that this new multimodal tumor treatment platform significantly improves the accuracy, safety, and effectiveness of local tumor ablation. At the same time, it breaks down tumor cells and vascular microcirculation in situ, releases a large amount of specific antigens, reshapes the tumor microenvironment, stimulates the body to produce persistent specific T cells to achieve anti-tumor immunity, effectively inhibits tumor recurrence and metastasis, and improves the long-term treatment benefits of patients.
As the chairman unit of the consortium, Shanghai Jiao Tong University and the Medical School of the Chinese Society of Biomedical Engineering have joined forces and crossed disciplines to gather multiple innovative technology platforms for minimally invasive diagnosis and treatment of tumors, and established the Multimodal Minimally Invasive Diagnosis and Treatment Innovation Technology Transformation Consortium for Tumors. On the same day, at the 2023 Innovation and Transformation Alliance Conference, Academician Teng Gaojun, President of the Interventional Physicians Branch of the Chinese Medical Association and Dean of the Affiliated Zhongda Hospital of Southeast University, stated that organically combining the advantages of various new tumor treatment technologies to achieve clinical effects of 1+1>2 is an important direction for the development of modern tumor treatment technology, which coincides with the clinical exploration direction of multimodal tumor treatment systems.
Professor Su Bing, Director of the Shanghai Institute of Immunology, shared the basic research and exploration of the impact of tumor microenvironment on the effectiveness of different treatment methods. He stated that if multimodal methods can be used to regulate the tumor microenvironment of patients, it will bring new development opportunities for clinical tumor treatment.
As a joint venture unit of "Jiaofu", Professor Li Wentao from Fudan University Affiliated Cancer Hospital, from the perspective of clinical application exploration, using advanced analysis methods such as single-cell sequencing, has revealed that multimodal tumor treatment is expected to achieve a leapfrog development from local precise and safe lesion inactivation to systemic specific anti-tumor immune stimulation to inhibit recurrence and metastasis, bringing a new platform and hope for clinical tumor treatment, and depicting a new blueprint for the era of interventional immunity.
From the perspective of clinical experts, Yang Jijin, the chief physician of Changhai Hospital, believes that multimodal therapy technology can be widely applied to the treatment of various solid tumors, and the expansion of future lung applications is his most concerned direction. Professor Xiao Yueyong from the General Hospital of the People's Liberation Army focuses on the new intelligent surgical assistance function of multimodal system configuration, which can help doctors quickly, accurately, and safely complete multimodal tumor treatment, making this new technology possible to serve clinical practice faster. Dr. Long Jiang, Chief Physician of Shanghai First People's Hospital, hopes that multimodal tumor treatment can assist in the progression of non-surgical patients and provide more patients with opportunities for curative treatment.
In the future, the Multimodal Tumor Minimally Invasive Diagnosis and Treatment Innovation Transformation Alliance will integrate intelligent medical imaging technology, medical robot technology, and biological therapy technology to build a new self specific immune tumor treatment ecosystem, launch more innovative treatment platforms such as multimodal tumor treatment systems, and work together to promote the continuous development of innovative tumor therapies, bringing more innovative diagnostic and therapeutic tools to clinical practice and benefiting cancer patients.
